Benzinga · Oct 15, 2026
Senti Biosciences Says Stockholders Approve Merger With ST NewCo; Approve Reverse Split Ratio Of 1-For-20 To 1-For-50
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001854270/000162828026065992/snti-20261015.htm
SN
NASDAQ · SNTI
Senti Biosciences, Inc.
Healthcare · Biotechnology
$0.18
Down-$0.00 (-0.73%)
Updated Nov 4, 2026, 11:13 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.33M
- P/E ratio
- -0.78
- Dividend yield
- 0.00%
- 52-week range
- $0.15 – $2.88
- Volume
- 267.7K
- Avg. volume
- 1.46M
Price performance · SNTI
SNTI price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SNTI closed at $0.18 after 21 trading sessions, down 44.92% for the selected period.
- Last close
- $0.18
- Period change
- -44.92%
- Period low
- $0.17
- Period high
- $0.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.184 | $0.1866 | $0.1733 | $0.1779 | 267.7K |
| Nov 2, 2026 | $0.172 | $0.2039 | $0.1555 | $0.188 | 897.14K |
| Oct 30, 2026 | $0.173 | $0.1999 | $0.1515 | $0.1651 | 1.6M |
| Oct 29, 2026 | $0.2139 | $0.238 | $0.2066 | $0.217 | 1.83M |
| Oct 28, 2026 | $0.181 | $0.2307 | $0.181 | $0.2151 | 9.99M |
| Oct 27, 2026 | $0.1676 | $0.195 | $0.156 | $0.1867 | 87.47M |
| Oct 26, 2026 | $0.186 | $0.186 | $0.1706 | $0.1751 | 70.91M |
| Oct 23, 2026 | $0.185 | $0.1888 | $0.1701 | $0.1884 | 366.39K |
| Oct 22, 2026 | $0.21 | $0.2135 | $0.1861 | $0.1905 | 201.48K |
| Oct 21, 2026 | $0.2209 | $0.2209 | $0.21 | $0.2175 | 252.39K |
| Oct 20, 2026 | $0.2136 | $0.23 | $0.2108 | $0.2277 | 290.81K |
| Oct 19, 2026 | $0.218 | $0.2342 | $0.2135 | $0.2268 | 309.13K |
| Oct 16, 2026 | $0.248 | $0.2531 | $0.2122 | $0.2249 | 3.5M |
| Oct 15, 2026 | $0.2399 | $0.2621 | $0.2399 | $0.2615 | 18.99M |
| Oct 14, 2026 | $0.2532 | $0.2616 | $0.2402 | $0.2408 | 168.19K |
| Oct 13, 2026 | $0.31 | $0.3105 | $0.252 | $0.255 | 302.82K |
| Oct 12, 2026 | $0.3108 | $0.3221 | $0.3099 | $0.3186 | 142.8K |
| Oct 9, 2026 | $0.3238 | $0.3238 | $0.31 | $0.3144 | 114.03K |
| Oct 8, 2026 | $0.3133 | $0.3293 | $0.3133 | $0.3217 | 248.72K |
| Oct 7, 2026 | $0.3131 | $0.35 | $0.313 | $0.33 | 330.74K |
| Oct 6, 2026 | $0.325 | $0.3401 | $0.3115 | $0.323 | 208.61K |
Latest SNTI news
The latest Smart Investors Daily articles mentioning SNTI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SNTI research
Overview
Company profile and research snapshot.
Company profile
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | Chardan Capital | Buy | — |
| Mar 30, 2026 | Chardan Capital | Buy | — |
| Dec 9, 2025 | Chardan Capital | Buy | — |
| Nov 21, 2025 | Leerink Partners | Outperform | — |
| Oct 14, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 24, 2026
Senti Biosciences Files Prospectus Covering Resale Of Up To 25,555,024 Shares Of Common Stock Offered By The Selling Securityholders
SENTI BIOSCIENCES HOLDINGS, INC.25,555,024 Shares of Common Stock Offered by the Selling SecurityholdersThis prospectus relates to the offer and sale from time to time by the selling securityholders (the "Selling
Benzinga · Jul 16, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's regular session. The company's market cap stands at $7.6 million. Agape ATP (NASDAQ:ATPC) shares moved upwards by
Benzinga · Jul 15, 2026
Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Celadon For Up To $60M In Milestone Payments Over Seven Years
Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
